Navigation Links
Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
Date:11/15/2012

therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as a twice-daily self-injection therapy for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes and presents when the body either does not produce enough insulin or becomes resistant to insulin, resulting in high levels of blood sugar. According to a June 2011 Lancet publication by Danaei and colleagues, an estimated 347 million adults worldwide suffered from type 2 diabetes in 2008; that number is expected to rise to 472 million by 2030. It is estimated that pre-diabetes, or impaired glucose tolerance (IGT), a condition that often leads to diabetes, affects a population roughly twice the size of the current diabetes population. The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded $400 billion in 2010. United Healthcare expects spending on diabetes and diabetes-related care to reach $500 billion by 2020 in the U.S. alone, and projects the cumulative cost of diabetes care will reach $3.4 t
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... 2014 Texas Governor Rick Perry, ... A&M Health Science Center CEO Brett Giroir, M.D., ... and Human Services (HHS), State of Texas and ... influenza vaccine manufacturing facility in Bryan, Texas, which ... the Texas A&M Biocorridor – a rapidly evolving ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... begun using a network infrastructure developed by Citrix ... over the Internet from a central office, the company ... able to provide 1,600 government employees across 45 departments ... from remote locations, including their homes, according to a ...
... - Working to help cell-phone users take advantage of ... University of Wisconsin-Madison engineers have developed a device that ... on even less battery power. , ,"When you've been ... you can feel how hot it gets," notes Zhenqiang ...
... an Internet search page: top, middle and down. A search ... times its 100 feet long. Today, e-commerce is like a ... then will it will float on the surface and be ... submarine, it will stay caught in some mysterious undercurrents or ...
Cached Biology Technology:Dane County improves law enforcement and community services 2UW-Madison technology to advance cell phones 2UW-Madison technology to advance cell phones 3Does your web site have visibility? 2Does your web site have visibility? 3
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... 2014 Elsevier, a world-leading provider of scientific, ... the Australasian Research Management Society (ARMS), recognized the ... the 5th Scopus Young Researcher of the Year ... at the National Convention Centre and in conjunction ... by guests representing Australia,s and New Zealand,s scientific ...
(Date:9/18/2014)... of the fish world, are the ideal animal in ... They,ve moved from the ocean into tens of thousands ... time changing their skeleton to adapt to the new ... of sticklebacks now have turned up one of the ... simple change in that gene,s regulation in a freshwater ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... research group of Dr. Frdric Charron, a researcher at the ... discovery which could help treat spinal cord injuries and neurodegenerative ... issue of the prestigious scientific journal Neuron . Patricia ... the IRCM, are listed as co-authors. The brain is ...
... of the most successful scientists within stem cell research, ... for biotech and pharmaceuticals, BIO 2009 in Atlanta, USA. ... Karolinska Institutet, SwedenBIO and Invest in Sweden Agency. ... one of the most exciting areas in science, and ...
... years ago, it was discovered that bacteria known as ... antibiotics have become the primary therapy used to combat the ... of the world population and is also a primary cause ... resistant to antibiotics. Now a study led by ...
Cached Biology News:Identification of a key molecular pathway required for brain neural circuit formation 2Glutamine supplements show promise in treating stomach ulcers 2Glutamine supplements show promise in treating stomach ulcers 3
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... in plasma from juvenile or male fish is ... chemicals (EDCs) with estrogenic effects in fish. Quantification ... for the estrogenic effects of EDCs in fish. ... double-antibody immunometric (sandwich) EIA for analyzing Vtg in ...
... synthetic peptide whose sequence is from rat SCAMP 5. The ... - N(217) - Q - P - Q - T - ... - N - Y - T - Y - S - ... control experiments with the polyclonal antibody that reacts with this product ...
... a novel target for which no antibody exists? ... custom antibodies for a variety of pharmaceutical, biotech ... to put our technology and expertise in antibody ... to our patented RabMAb development technology , High ...
Biology Products: